February 2024

Sementis was delighted to be recognised at the 2024 DMTC Annual Conference, and our CEO Dr Anne Collins the recipient of the Collaboration Award.

We would like to acknowledge the commitment of the whole Sementis team and our network of local and global experts that have diligently worked with us, and each other, to position our novel vaccine platform on the path to “pandemic ready”. Thank you.

On accepting the award Dr Collins commented, “Our collaboration with the DMTC Ltd Health Security Systems Australia Team and the practical support and connections are incredibly valuable to a small biotech. DMTC engaged global vaccine development experts Certara to undertake a technical assessment of the Sementis viral vector vaccine platform as part of their due diligence – an open process that has provided us with an independent assessment of the status of the technology and clear development pathway to the clinic. This is something unique to DMTC.”

Read more at DMTC’s official press release dmtc.com.au/news/well-deserved-recognition-for-vaccine-collaboration-leader/